This data de-risks the ongoing pivotal EMBRAVE3 trial and positions elsunersen as a best-in-class candidate for SCN2A-DEE. Traders should monitor upcoming regulatory interactions and potential fast-track expansion; consider positioning ahead of EMBRAVE3 readout. Competitive moat strengthened by PRIME and orphan designations in both US and EU.
PRAX drugs
PRAX drug pipeline →- ▲ relutrigine 8/10 Filed/PDUFA (NDA under priority review) · PDUFA date Dec 27, 2026
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027
- ● vormatrigine 5/10 Phase 3
- ◆ elsunersen 4/10 Phase 2/3 (registrational)
- ● PRAX-050 Fresh report · subscribers
- 4 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $310.11entry
- T+1 · 7mo ago −1.10%α −1.17% · $306.69
- T+5 · 7mo ago +2.22%α −1.91% · $317.00
- T+20 · 7mo ago +8.87%α −0.12% · $337.61
- T+60 · 5mo ago +3.06%α −10.41% · $319.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with SCN2A developmental and epileptic encephalopathy (DEE), showing a 77% placebo-adjusted seizure reduction (p=0.015) and meaningful functional improvements across sleep, motor function, and attention. The drug was well-tolerated with no drug-related serious adverse events, supporting its potential as a first disease-modifying therapy for this rare genetic epilepsy.
Key Facts
- Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in SCN2A-DEE patients
- 71% of treated patients had >50% seizure reduction; 57% had at least 28 days seizure-free
- 100% of elsunersen patients showed functional improvements vs. none in placebo
- No treatment-emergent or serious adverse events related to the drug
- All nine patients continued into open-label extension with sustained benefit up to one year
Financial Impact
High-value catalyst for a rare disease with no approved therapies; potential peak sales in the hundreds of millions given orphan drug designations and precision CNS focus
Risk Factors
- Small sample size (n=9) limits statistical power despite significance
- Pivotal EMBRAVE3 trial results may not replicate Part A efficacy
- Regulatory path may require additional data beyond current trial design
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268372 |
Track record
16 reports on PRAX
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers